Andrew Zolopa

Publications

• Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. Grant PM, Komarow L, Lederman MM, Pahwa S, Zolopa AR, Andersen J, Asmuth DM, Devaraj S, Pollard RB, Richterman A, Kanthikeel S, Sereti I. J Infect Dis. 2012; 206 (11): 1715-23
• Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients. Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, Mills A, Wohl D, Liu H, Rhee M, Szwarcberg J. J Int AIDS Soc. 2012; 15 (6): 18219
• Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia-Cancio PV, Zolopa A, Robbins GK, Kagan R, Israelski D, Shafer RW. Antimicrob Agents Chemother. 2012; 56 (5): 2305-13
• When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Grant PM, Zolopa AR. Curr HIV/AIDS Rep. 2012; 9 (3): 251-8
• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. AIDS. 2011; 25 (2): 211-20
• Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK. J Infect Dis. 2010; 201 (6): 814-22
• Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, Grunfeld C, Shlipak M, Tien PC. J Acquir Immune Defic Syndr. 2010; 53 (1): 102-6
• Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Grant PM, Aberg JA, Zolopa AR. Clin Infect Dis. 2010; 51 (8): 984-5; author reply 987-9
• Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D. AIDS. 2010; 24 (3): 365-71
• HIV-1 protease mutations and protease inhibitor cross-resistance. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW. Antimicrob Agents Chemother. 2010; 54 (10): 4253-61
• Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C. J Acquir Immune Defic Syndr. 2010; 55 (3): 316-22
• International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR. Antimicrob Agents Chemother. 2010; 54 (4): 1520-5
• Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Grant PM, Zolopa AR. Curr Opin Investig Drugs. 2010; 11 (8): 901-10
• Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Antimicrob Agents Chemother. 2010; 54 (6): 2473-9
• Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM, Eron J, Sanne I, Powderly W, Hogg E, Suckow C, Zolopa A. PLoS One. 2010; 5 (7): e11416
• The evolution of HIV treatment guidelines: current state-of-the-art of ART. Zolopa AR, Antiviral Res. 2010; 85 (1): 241-4
• Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L. PLoS One. 2009; 4 (5): e5575
• Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, Alston-Smith B, Acosta EP. J Acquir Immune Defic Syndr. 2009; 50 (3): 290-3
• Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Grant P, Zolopa A. Curr HIV/AIDS Rep. 2009; 6 (2): 63-7
• Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A. Clin Infect Dis. 2009; 48 (5): 680-2
• Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Shahriar R, Rhee SY, Liu TF, Fessel WJ, Scarsella A, Towner W, Holmes SP, Zolopa AR, Shafer RW. Antimicrob Agents Chemother. 2009; 53 (11): 4869-78
• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. J Clin Virol. 2009; 46 (4): 305-8
• The use of resistance testing in the management of HIV-1-infected patients. Grant PM, Zolopa AR. Curr Opin HIV AIDS. 2009; 4 (6): 474-80
• Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D. J Infect Dis. 2008; 198 (4): 470-80
• Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Grant P, Zolopa A. J HIV Ther. 2008; 13 (2): 36-9
• Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. DeJesus E, Gottlieb MS, Gathe JC, Greenberg ML, Guittari CJ, Zolopa AR. Antimicrob Agents Chemother. 2008; 52 (12): 4315-9
• Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Grant P, Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen C, Harrington R, Kempf D, Zolopa A. Antimicrob Agents Chemother. 2008; 52 (11): 4050-6
• Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, Agarwala S, Child M, Bertz R, Hosey L, Haas DW. Antimicrob Agents Chemother. 2007; 51 (9): 3104-10
• Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. Liu M, Holodniy M, Zolopa AR, Shafer RW. MedGenMed. 2006; 8 (1): 24
• Incorporating drug-resistance measurements into the clinical management of HIV-1 infection. Zolopa AR, J Infect Dis. 2006: 194 Suppl 1 S59-64
• N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. AIDS Res Hum Retroviruses. 2006; 22 (12): 1300-5
• Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR. Clin Infect Dis. 2005; 41 (1): 92-9
• HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW. J Infect Dis. 2005; 192 (3): 456-65
• Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW. AIDS. 2003; 17 (6): 791-9
• Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J, Shafer RW. J Infect Dis. 2003; 188 (3): 397-405
• Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. J Virol. 2003; 77 (8): 4836-47
• Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Kantor R, Fessel WJ, Zolopa AR, Israelski D, Shulman N, Montoya JG, Harbour M, Schapiro JM, Shafer RW. Antimicrob Agents Chemother. 2002; 46 (4): 1086-92
• Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. J Acquir Immune Defic Syndr. 2002; 31 (2): 121-7
• Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E. Antimicrob Agents Chemother. 2002; 46 (12): 3907-16
• Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA. J Acquir Immune Defic Syndr. 2001; 27 (4): 377-80
• HIV drug resistance testing: an update for the clinician. Rice HL, Zolopa AR. AIDS Clin Care. 2001; 13 (10): 89-91, 94-6, 100
• High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. J Clin Microbiol. 2001; 39 (4): 1522-9
• Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J. AIDS. 2001; 15 (9): 1125-32
• Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. J Acquir Immune Defic Syndr. 2000; 23 (3): 221-6
• Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC. AIDS Res Hum Retroviruses. 2000; 16 (14): 1357-69
• Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. J Infect Dis. 1999; 179 (6): 1356-64
• HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. Ann Intern Med. 1999; 131 (11): 813-21
• Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS. Eckburg PB, Zolopa AR, Montoya JG. Clin Infect Dis. 1999; 29 (1): 212-3
• Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity. Kemper CA, Zolopa AR, Hamilton JR, Fenstersheib M, Bhatia G, Deresinski SC. AIDS. 1992; 6 (11): 1321-5